A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Permanent neonatal diabetes mellitus (PNDM) is commonly caused by pathogenic variants in KCNJ11 that impair insulin secretion through ATP-sensitive potassium (K) channel dysfunction. Sulfonylureas (SUs) can stimulate insulin secretion and enable insu…
BACKGROUND AND AIM: Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists is increasing among reproductive-aged women for obesity, diabetes, polycystic ovary sy…
BACKGROUND: Orforglipron is a novel non-peptide (GLP-1) receptor agonist designed for daily oral administration without food or water restrictions. This study aimed to compare the efficacy and safety of orforglipron with oral semaglutide in individua…
AIMS: Obesity adversely affects atrial fibrillation (AF) outcomes and is associated with higher recurrence after catheter ablation. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) promote weight loss and improve metabolic inflammation, but their…
OBJECTIVE: Oral semaglutide contains salcaprozate sodium, which promotes the opening of epithelial tight junctions and increases gastric pH to prevent its degradation; these actions together improve absorption. Proton pump inhibitors (PPIs) increase…
BACKGROUND: User experience has a significant impact on pharmaceutical drug effectiveness. Social media platforms like X (formerly Twitter) have become prominent spaces where individuals share their medication-related experiences, especially with wid…
BACKGROUND AND AIMS: Semaglutide and tirzepatide have been shown to reduce body weight, improve health status, and lower rates of clinical events in patients with obesity and heart failure with preserved ejection fraction (HFpEF). Although recent dat…
Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and the dual GIP/GLP-1 RA tirzepatide, are widely prescribed for type 2 diabetes mellitus (T2DM). Their musculoske…
BACKGROUND: Both tirzepatide and semaglutide, once-weekly injectable incretin-based agents, have demonstrated substantial weight-reducing potential in populations with overweight or obesity. However, the relative effectiveness of these two agents rem…
BACKGROUND: Diabetic nephropathy (DN) is a major microvascular complication of type 2 diabetes and a leading cause of end-stage renal disease. Both canagliflozin and semaglutide are recommended for diabetic nephropathy, yet direct evidence comparing…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained rapid popularity for both medical and consumer-directed weight loss. This growth has been accompanied by increased public discussion regarding facial aesthetic changes, com…
BACKGROUND: Glucagon-like peptide-1 agonists like semaglutide are effective treatments for obesity. High costs may create economic barriers. This study examines the association between income and prescriptions for semaglutide for weight loss. METHODS…
IMPORTANCE: Patients who have undergone bariatric surgery have an elevated risk for alcohol use disorder (AUD). Incretin-based therapies (IBTs) may be associated with reward pathways in addition to weight loss. OBJECTIVE: To evaluate whether IBT afte…
PURPOSE: Obesity remains a significant public health issue in the Western world, affecting millions of Americans and contributing to chronic conditions such as diabetes and hypertension. In June 2021, the Food and Drug Administration approved semaglu…
BACKGROUND: Patients with type 2 diabetes mellitus (T2DM) have a high-risk condition of developing cardiovascular disease, and therefore, therapeutic strategies should consider cardiovascular risk reduction. Previously, we demonstrated that circulati…
Background Incretin-based therapies have emerged as effective strategies for obesity and type 2 diabetes mellitus (T2DM) management. Semaglutide and tirzepatide are among the most promising agents. Real-world data in Bangladesh on their efficacy, lif…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide (Wegovy®), are increasingly used for weight management in both adult and pediatric populations. Their mechanism of delayed gastric emptying raises concern for aspiration dur…